AngioDynamics’ (ANGO) “Buy” Rating Reaffirmed at Canaccord Genuity Group

AngioDynamics (NASDAQ:ANGO)‘s stock had its “buy” rating restated by investment analysts at Canaccord Genuity Group in a research note issued on Friday, Benzinga reports. They currently have a $20.00 price objective on the medical instruments supplier’s stock. Canaccord Genuity Group’s price objective suggests a potential upside of 78.95% from the company’s previous close.

Several other equities analysts have also issued reports on ANGO. HC Wainwright lifted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.50.

AngioDynamics Stock Performance

NASDAQ ANGO traded down $0.05 during trading on Friday, hitting $11.18. The stock had a trading volume of 321,088 shares, compared to its average volume of 496,473. The stock has a market capitalization of $469.95 million, a price-to-earnings ratio of -12.79 and a beta of 0.30. AngioDynamics has a one year low of $9.39 and a one year high of $16.29. The stock has a 50 day simple moving average of $15.39 and a 200 day simple moving average of $13.11.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts predict that AngioDynamics will post -0.25 EPS for the current year.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.00% of the stock is currently owned by company insiders.

Institutional Trading of AngioDynamics

A number of hedge funds have recently bought and sold shares of ANGO. Integrated Wealth Concepts LLC acquired a new stake in AngioDynamics in the 2nd quarter valued at about $38,000. Corient Private Wealth LP acquired a new stake in AngioDynamics in the 2nd quarter valued at about $134,000. Public Employees Retirement System of Ohio acquired a new stake in AngioDynamics in the 2nd quarter valued at about $64,000. Bank of America Corp DE acquired a new stake in AngioDynamics in the 2nd quarter valued at about $4,490,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new stake in AngioDynamics in the 2nd quarter valued at about $589,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of $80.9 million, slightly above consensus, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, led by 13.2% growth in Med Tech sales. Auryon sales rose 14.7% and NanoKnife sales climbed 29.0%. AngioDynamics Fiscal Q1 Results
• Positive Sentiment: The company reiterated fiscal 2027 revenue guidance of $336 million to $341 million and EPS guidance of $(0.29) to $(0.24), broadly in line with analyst expectations. Canaccord Genuity reaffirmed its Buy rating and maintained a $20 price target, implying substantial potential upside from the referenced $11.23 price. AngioDynamics Outlook
• Neutral Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The appointment brings an experienced medical-technology executive to the company, but the leadership change introduces near-term execution uncertainty and contributed to the weak market reaction. CEO Appointment
• Negative Sentiment: Despite improved results, AngioDynamics remains unprofitable, with a reported GAAP net loss and negative margins. The company used $15.3 million in operating cash during the quarter and held $34.0 million in cash at quarter-end, heightening concerns about profitability and liquidity. The unchanged guidance also failed to provide a stronger catalyst after the earnings release.

About AngioDynamics

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.